Gout Market Research Report Information By Treatment and Diagnosis (Diagnosis, Treatment (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, Others)), Application (Acute Gout, Chronic Gout), End User (Hospitals & Clinics, Specialty Centers, Others) and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2032

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 13

1.1 OVERVIEW 13

2 MARKET INTRODUCTION 14

2.1 DEFINITION 14

2.2 SCOPE OF THE STUDY 14

2.3 RESEARCH OBJECTIVE 14

2.4 MARKET STRUCTURE 15

2.5 ASSUMPTIONS & LIMITATIONS 15

3 RESEARCH METHODOLOGY 16

3.1 DATA MINING 16

3.2 SECONDARY RESEARCH 17

3.3 PRIMARY RESEARCH 18

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19

3.5 FORECASTING TECHNIQUES 20

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21

3.6.1 BOTTOM-UP APPROACH 22

3.6.2 TOP-DOWN APPROACH 22

3.7 DATA TRIANGULATION 23

3.8 VALIDATION 23

4 MARKET DYNAMICS 24

4.1 OVERVIEW 24

4.2 DRIVERS 25

4.2.1 INCREASING PREVALENCE OF GOUT 25

4.2.2 RISING HEALTHCARE EXPENDITURE 25

4.2.3 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 26

4.3 RESTRAINTS 27

4.3.1 SIDE EFFECTS OF GOUT THERAPEUTIC DRUGS 27

4.3.2 LACK OF AWARENESS AMONG PEOPLE 28

4.4 OPPORTUNITY 28

4.4.1 RISING NUMBER OF STRATEGIC INITIATIVES 28

5 MARKET FACTOR ANALYSIS 29

5.1 VALUE CHAIN ANALYSIS 29

5.1.1 R&D 30

5.1.2 MANUFACTURING 30

5.1.3 DISTRIBUTION & SALES 30

5.1.4 POST-SALES MONITORING 30

5.2 PORTER'S FIVE FORCES MODEL 31

5.2.1 THREAT OF NEW ENTRANTS 31

5.2.2 BARGAINING POWER OF SUPPLIERS 32

5.2.3 THREAT OF SUBSTITUTES 32

5.2.4 BARGAINING POWER OF BUYERS 32

5.2.5 INTENSITY OF RIVALRY 32

5.3 IMPACT OF COVID-19 ON THE GLOBAL GOUT MARKET 33

5.3.1 IMPACT ON VALUE CHAIN 33

5.3.2 IMPACT ON SUPPLY CHAIN 33

5.3.3 IMPACT ON KEY PLAYERS 33

6 GLOBAL GOUT MARKET, BY DIAGNOSIS & TREATMENT 34

6.1 OVERVIEW 34

6.2 DIAGNOSIS 36

6.3 TREATMENT 36

6.3.1 NSAIDS 37

6.3.2 CORTICOSTEROIDS 37

6.3.3 COLCHICINE 38

6.3.4 URATE-LOWERING AGENTS 38

6.3.5 OTHERS 39

7 GLOBAL GOUT MARKET, BY APPLICATION 40

7.1 OVERVIEW 40

7.2 ACUTE GOUT 41

7.3 CHRONIC GOUT 42

8 GLOBAL GOUT MARKET, BY END USER 43

8.1 OVERVIEW 43

8.2 HOSPITALS & CLINICS 44

8.3 SPECIALTY CENTERS 45

8.4 OTHERS 45

9 GLOBAL GOUT MARKET, BY REGION 46

9.1 OVERVIEW 46

9.2 NORTH AMERICA 48

9.2.1 US 50

9.2.2 CANADA 51

9.3 EUROPE 52

9.3.1 GERMANY 54

9.3.2 UK 55

9.3.3 FRANCE 56

9.3.4 ITALY 57

9.3.5 SPAIN 58

9.3.6 REST OF EUROPE 59

9.4 ASIA-PACIFIC 61

9.4.1 CHINA 63

9.4.2 JAPAN 64

9.4.3 INDIA 65

9.4.4 AUSTRALIA 66

9.4.5 SOUTH KOREA 67

9.4.6 REST OF ASIA PACIFIC 68

9.5 REST OF THE WORLD 69

9.5.1 MIDDLE EAST 71

9.5.2 AFRICA 72

9.5.3 LATIN AMERICA 73

10 COMPETITIVE LANDSCAPE 74

10.1 OVERVIEW 74

10.2 COMPETITIVE BENCHMARKING 75

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL GOUT MARKET 76

10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL GOUT MARKET 77

10.5 KEY DEVELOPMENT ANALYSIS 77

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 78

10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL 78

10.6.2 PARTNERSHIPS/ AGREEMENTS 78

10.7 FINANCIAL MATRIX 78

10.7.1 SALES (USD MILLION), 2022 78

10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022 79

11 COMPANY PROFILES 80

11.1 NOVARTIS AG 80

11.1.1 COMPANY OVERVIEW 80

11.1.2 FINANCIAL OVERVIEW 81

11.1.3 PRODUCTS OFFERED 81

11.1.4 KEY DEVELOPMENTS 81

11.1.5 SWOT ANALYSIS 82

11.1.6 KEY STRATEGIES 82

11.2 LANNETT 83

11.2.1 COMPANY OVERVIEW 83

11.2.2 FINANCIAL OVERVIEW 83

11.2.3 PRODUCTS OFFERED 84

11.2.4 KEY DEVELOPMENTS 84

11.2.5 KEY STRATEGIES 84

11.3 HORIZON THERAPEUTICS PLC 85

11.3.1 COMPANY OVERVIEW 85

11.3.2 FINANCIAL OVERVIEW 86

11.3.3 PRODUCTS OFFERED 86

11.3.4 KEY DEVELOPMENTS 86

11.3.5 KEY STRATEGIES 87

11.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED 88

11.4.1 COMPANY OVERVIEW 88

11.4.2 FINANCIAL OVERVIEW 88

11.4.3 PRODUCTS OFFERED 89

11.4.4 KEY DEVELOPMENTS 89

11.4.5 KEY STRATEGIES 89

11.5 GLAXOSMITHKLINE PLC 90

11.5.1 COMPANY OVERVIEW 90

11.5.2 FINANCIAL OVERVIEW 91

11.5.3 PRODUCTS OFFERED 91

11.5.4 KEY DEVELOPMENTS 91

11.5.5 SWOT ANALYSIS 92

11.5.6 KEY STRATEGIES 92

11.6 REGENERON PHARMACEUTICALS, INC. 93

11.6.1 COMPANY OVERVIEW 93

11.6.2 FINANCIAL OVERVIEW 93

11.6.3 PRODUCTS OFFERED 94

11.6.4 KEY DEVELOPMENTS 94

11.6.5 KEY STRATEGIES 94

11.7 TEIJIN LIMITED 95

11.7.1 COMPANY OVERVIEW 95

11.7.2 FINANCIAL OVERVIEW 95

11.7.3 PRODUCTS OFFERED 96

11.7.4 KEY DEVELOPMENTS 96

11.7.5 SWOT ANALYSIS 96

11.7.6 KEY STRATEGIES 96

11.8 VIATRIS INC. 97

11.8.1 COMPANY OVERVIEWS 97

11.8.2 FINANCIAL OVERVIEW 98

11.8.3 PRODUCTS OFFERED 98

11.8.4 KEY DEVELOPMENTS 98

11.8.5 SWOT ANALYSIS 99

11.8.6 KEY STRATEGIES 99

11.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. 100

11.9.1 COMPANY OVERVIEW 100

11.9.2 FINANCIAL OVERVIEW 101

11.9.3 PRODUCTS OFFERED 101

11.9.4 KEY DEVELOPMENTS 102

11.9.5 SWOT ANALYSIS 102

11.9.6 KEY STRATEGIES 102

11.10 ROMEG THERAPEUTICS, LLC 103

11.10.1 COMPANY OVERVIEW 103

11.10.2 FINANCIAL OVERVIEW 103

11.10.3 PRODUCTS OFFERED 103

11.10.4 KEY DEVELOPMENTS 103

11.10.5 KEY STRATEGIES 103

12 APPENDIX 104

12.1 REFERENCES 104

12.2 WORLD HEALTH ORGANIZATION 104

12.3 THE GOUT EDUCATION SOCIETY 104

12.4 ARTHRITIS FOUNDATION 104

12.5 AMERICAN ARTHRITIS SOCIETY 104

12.6 SOUTH AFRICAN RHEUMATISM AND ARTHRITIS ASSOCIATION (SARAA) 104

12.7 EMIRATES ARTHRITIS FOUNDATION 104

12.8 ARTHRITIS FOUNDATION OF ASIA 104

12.9 OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL (OARSI) 104

12.10 SOAR - SOCIETY FOR OSTEOARTHRITIS RESEARCH 104

12.11 THE EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY 104

12.12 RELATED REPORTS 105

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 15

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18

TABLE 3 GLOBAL GOUT MARKET, BY DIAGNOSIS AND TREATMENT, 2019–2032 (USD MILLION) 35

TABLE 4 GLOBAL GOUT MARKET, FOR DIAGNOSIS, BY REGION, 2019–2032 (USD MILLION) 36

TABLE 5 GLOBAL GOUT MARKET, FOR TREATMENT, BY REGION, 2019–2032 (USD MILLION) 36

TABLE 6 GLOBAL GOUT MARKET, FOR NSAIDS, BY REGION, 2019–2032 (USD MILLION) 37

TABLE 7 GLOBAL GOUT MARKET, FOR CORTICOSTEROIDS, BY REGION, 2019–2032 (USD MILLION) 37

TABLE 8 GLOBAL GOUT MARKET, FOR COLCHICINE, BY REGION, 2019–2032 (USD MILLION) 38

TABLE 9 GLOBAL GOUT MARKET, FOR URATE-LOWERING AGENTS, BY REGION, 2019–2032 (USD MILLION) 38

TABLE 10 GLOBAL GOUT MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 39

TABLE 11 GLOBAL GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 41

TABLE 12 GLOBAL GOUT MARKET, FOR ACUTE GOUT, BY REGION, 2019–2032 (USD MILLION) 41

TABLE 13 GLOBAL GOUT MARKET, FOR CHRONIC GOUT, BY REGION, 2019–2032 (USD MILLION) 42

TABLE 14 GLOBAL GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 44

TABLE 15 GLOBAL GOUT MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2019–2032 (USD MILLION) 44

TABLE 16 GLOBAL GOUT MARKET, FOR SPECIALTY CENTERS, BY REGION, 2019–2032 (USD MILLION) 45

TABLE 17 GLOBAL GOUT MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 45

TABLE 18 GLOBAL: GOUT MARKET, BY REGION, 2019–2032 (USD MILLION) 46

TABLE 19 NORTH AMERICA: GOUT MARKET, BY COUNTRY, 2019-2032 (USD MILLION) 48

TABLE 20 NORTH AMERICA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019-2032 (USD MILLION) 49

TABLE 21 NORTH AMERICA: GOUT MARKET, BY TREATMENT, 2019-2032 (USD MILLION) 49

TABLE 22 NORTH AMERICA: GOUT MARKET, BY APPLICATION, 2019-2032 (USD MILLION) 49

TABLE 23 NORTH AMERICA: GOUT MARKET, BY END USER, 2019-2032 (USD MILLION) 49

TABLE 24 US: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019-2032 (USD MILLION) 50

TABLE 25 US: GOUT MARKET, BY TREATMENT, 2019-2032 (USD MILLION) 50

TABLE 26 US: GOUT MARKET, BY APPLICATION, 2019-2032 (USD MILLION) 50

TABLE 27 US: GOUT MARKET, BY END USER, 2019-2032 (USD MILLION) 50

TABLE 28 CANADA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019-2032 (USD MILLION) 51

TABLE 29 CANADA: GOUT MARKET, BY TREATMENT, 2019-2032 (USD MILLION) 51

TABLE 30 CANADA: GOUT MARKET, BY APPLICATION, 2019-2032 (USD MILLION) 51

TABLE 31 CANADA: GOUT MARKET, BY END USER, 2019-2032 (USD MILLION) 51

TABLE 32 EUROPE: GOUT MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 53

TABLE 33 EUROPE: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019-2032 (USD MILLION) 53

TABLE 34 EUROPE: GOUT MARKET, BY TREATMENT, 2019-2032 (USD MILLION) 53

TABLE 35 EUROPE: GOUT MARKET, BY APPLICATION, 2019-2032 (USD MILLION) 54

TABLE 36 EUROPE: GOUT MARKET, BY END USER, 2019-2032 (USD MILLION) 54

TABLE 37 GERMANY: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019-2032 (USD MILLION) 54

TABLE 38 GERMANY: GOUT MARKET, BY TREATMENT, 2019-2032 (USD MILLION) 54

TABLE 39 GERMANY: GOUT MARKET, BY APPLICATION, 2019-2032 (USD MILLION) 55

TABLE 40 GERMANY: GOUT MARKET, BY END USER, 2019-2032 (USD MILLION) 55

TABLE 41 UK: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019-2032 (USD MILLION) 55

TABLE 42 UK: GOUT MARKET, BY TREATMENT, 2019-2032 (USD MILLION) 55

TABLE 43 UK: GOUT MARKET, BY APPLICATION, 2019-2032 (USD MILLION) 56

TABLE 44 UK: GOUT MARKET, BY END USER, 2019-2032 (USD MILLION) 56

TABLE 45 FRANCE: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019-2032 (USD MILLION) 56

TABLE 46 FRANCE: GOUT MARKET, BY TREATMENT, 2019-2032 (USD MILLION) 56

TABLE 47 FRANCE: GOUT MARKET, BY APPLICATION, 2019-2032 (USD MILLION) 57

TABLE 48 FRANCE: GOUT MARKET, BY END USER, 2019-2032 (USD MILLION) 57

TABLE 49 ITALY: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019-2032 (USD MILLION) 57

TABLE 50 ITALY: GOUT MARKET, BY TREATMENT, 2019-2032 (USD MILLION) 57

TABLE 51 ITALY: GOUT MARKET, BY APPLICATION, 2019-2032 (USD MILLION) 58

TABLE 52 ITALY: GOUT MARKET, BY END USER, 2019-2032 (USD MILLION) 58

TABLE 53 SPAIN: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019-2032 (USD MILLION) 58

TABLE 54 SPAIN: GOUT MARKET, BY TREATMENT, 2019-2032 (USD MILLION) 58

TABLE 55 SPAIN: GOUT MARKET, BY APPLICATION, 2019-2032 (USD MILLION) 59

TABLE 56 SPAIN: GOUT MARKET, BY END USER, 2019-2032 (USD MILLION) 59

TABLE 57 REST OF EUROPE: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019-2032 (USD MILLION) 59

TABLE 58 REST OF EUROPE: GOUT MARKET, BY TREATMENT, 2019-2032 (USD MILLION) 59

TABLE 59 REST OF EUROPE: GOUT MARKET, BY APPLICATION, 2019-2032 (USD MILLION) 60

TABLE 60 REST OF EUROPE: GOUT MARKET, BY END USER, 2019-2032 (USD MILLION) 60

TABLE 61 ASIA-PACIFIC: GOUT MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 61

TABLE 62 ASIA-PACIFIC: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019–2032 (USD MILLION) 62

TABLE 63 ASIA-PACIFIC: GOUT MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 62

TABLE 64 ASIA-PACIFIC: GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 62

TABLE 65 ASIA-PACIFIC: GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 62

TABLE 66 CHINA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019–2032 (USD MILLION) 63

TABLE 67 CHINA: GOUT MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 63

TABLE 68 CHINA: GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 63

TABLE 69 CHINA: GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 63

TABLE 70 JAPAN: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019–2032 (USD MILLION) 64

TABLE 71 JAPAN: GOUT MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 64

TABLE 72 JAPAN: GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 64

TABLE 73 JAPAN: GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 64

TABLE 74 INDIA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019–2032 (USD MILLION) 65

TABLE 75 INDIA: GOUT MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 65

TABLE 76 INDIA: GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 65

TABLE 77 INDIA: GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 65

TABLE 78 AUSTRALIA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019–2032 (USD MILLION) 66

TABLE 79 AUSTRALIA: GOUT MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 66

TABLE 80 AUSTRALIA: GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 66

TABLE 81 AUSTRALIA: GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 66

TABLE 82 SOUTH KOREA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019–2032 (USD MILLION) 67

TABLE 83 SOUTH KOREA: GOUT MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 67

TABLE 84 SOUTH KOREA: GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 67

TABLE 85 SOUTH KOREA: GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 67

TABLE 86 REST OF ASIA PACIFIC: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019–2032 (USD MILLION) 68

TABLE 87 REST OF ASIA PACIFIC: GOUT MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 68

TABLE 88 REST OF ASIA PACIFIC: GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 68

TABLE 89 REST OF ASIA PACIFIC: GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 68

TABLE 90 REST OF THE WORLD: GOUT MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 69

TABLE 91 REST OF THE WORLD: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019–2032 (USD MILLION) 70

TABLE 92 REST OF THE WORLD: GOUT MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 70

TABLE 93 REST OF THE WORLD: GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 70

TABLE 94 REST OF THE WORLD: GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 70

TABLE 95 MIDDLE EAST: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019–2032 (USD MILLION) 71

TABLE 96 MIDDLE EAST: GOUT MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 71

TABLE 97 MIDDLE EAST: GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 71

TABLE 98 MIDDLE EAST: GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 71

TABLE 99 AFRICA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019–2032 (USD MILLION) 72

TABLE 100 AFRICA: GOUT MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 72

TABLE 101 AFRICA: GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 72

TABLE 102 AFRICA: GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 72

TABLE 103 LATIN AMERICA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2019–2032 (USD MILLION) 73

TABLE 104 LATIN AMERICA: GOUT MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 73

TABLE 105 LATIN AMERICA: GOUT MARKET, BY APPLICATION, 2019–2032 (USD MILLION) 73

TABLE 106 LATIN AMERICA: GOUT MARKET, BY END USER, 2019–2032 (USD MILLION) 73

TABLE 107 MAJOR PLAYERS IN THE GLOBAL GOUT MARKET 74

TABLE 108 MOST ACTIVE PLAYER IN THE GLOBAL GOUT MARKET 77

TABLE 109 PRODUCT LAUNCH/ PRODUCT APPROVAL 78

TABLE 110 PARTNERSHIPS/ AGREEMENTS 78

TABLE 111 NOVARTIS AG: PRODUCTS OFFERED 81

TABLE 112 LANNETT: PRODUCTS OFFERED 84

TABLE 113 HORIZON THERAPEUTICS PLC: PRODUCTS OFFERED 86

TABLE 114 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED 89

TABLE 115 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED 91

TABLE 116 REGENERON PHARMACEUTICALS, INC.: PRODUCTS OFFERED 94

TABLE 117 TEIJIN LIMITED: PRODUCTS OFFERED 96

TABLE 118 VIATRIS INC.: PRODUCTS OFFERED 98

TABLE 119 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.: PRODUCTS OFFERED 101

TABLE 120 ROMEG THERAPEUTICS, LLC: PRODUCTS OFFERED 103

TABLE 121 ROMEG THERAPEUTICS, LLC: KEY DEVELOPMENTS 103

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 13

FIGURE 2 GLOBAL GOUT MARKET 15

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 21

FIGURE 4 MARKET DYNAMICS: GLOBAL GOUT MARKET 24

FIGURE 5 DRIVER IMPACT ANALYSIS 26

FIGURE 6 RESTRAINT IMPACT ANALYSIS 28

FIGURE 7 VALUE CHAIN: GLOBAL GOUT MARKET 29

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GOUT MARKET 31

FIGURE 9 GLOBAL GOUT MARKET SHARE, BY DIAGNOSIS AND TREATMENT, 2022 (%) 34

FIGURE 10 GLOBAL GOUT MARKET, BY DIAGNOSIS AND TREATMENT, 2022 (USD MILLION) 34

FIGURE 11 GLOBAL GOUT MARKET SHARE, BY TREATMENT, 2022 (%) 35

FIGURE 12 GLOBAL GOUT MARKET, BY TREATMENT, 2022 (USD MILLION) 35

FIGURE 13 GLOBAL GOUT MARKET SHARE, BY APPLICATION, 2022 (%) 40

FIGURE 14 GLOBAL GOUT MARKET, BY APPLICATION, 2022 (USD MILLION) 40

FIGURE 15 GLOBAL GOUT MARKET SHARE, BY END USER, 2022 (%) 43

FIGURE 16 GLOBAL GOUT MARKET, BY END USER, 2022 (USD MILLION) 43

FIGURE 17 GLOBAL: GOUT MARKET, BY REGION 2022 & 2030 (USD MILLION) 46

FIGURE 18 GLOBAL: GOUT MARKET SHARE, BY REGION 2022 (%) 47

FIGURE 19 NORTH AMERICA: GOUT MARKET, BY COUNTRY, 2022 (%) 48

FIGURE 20 EUROPE: GOUT MARKET SHARE, BY COUNTRY 2022 (%) 52

FIGURE 21 ASIA-PACIFIC: GOUT MARKET SHARE, BY COUNTRY, 2022 (%) 61

FIGURE 22 REST OF THE WORLD: GOUT MARKET SHARE, BY COUNTRY, 2022 (%) 69

FIGURE 23 BENCHMARKING OF MAJOR COMPETITORS 75

FIGURE 24 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL GOUT MARKET 76

FIGURE 25 GLOBAL GOUT MARKET: COMPETITIVE LANDSCAPE 77

FIGURE 26 SALES, 2022 78

FIGURE 27 RESEARCH & DEVELOPMENT EXPENDITURE, 2022 79

FIGURE 28 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 81

FIGURE 29 NOVARTIS AG: SWOT ANALYSIS 82

FIGURE 30 LANNETT: FINANCIAL OVERVIEW SNAPSHOT 83

FIGURE 31 HORIZON THERAPEUTICS PLC: FINANCIAL OVERVIEW SNAPSHOT 86

FIGURE 32 TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL OVERVIEW SNAPSHOT 88

FIGURE 33 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 91

FIGURE 34 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 92

FIGURE 35 REGENERON PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT 93

FIGURE 36 TEIJIN LIMITED: FINANCIAL OVERVIEW SNAPSHOT 95

FIGURE 37 TEIJIN LIMITED: SWOT ANALYSIS 96

FIGURE 38 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT 98

FIGURE 39 VIATRIS INC: SWOT ANALYSIS 99

FIGURE 40 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.: FINANCIAL OVERVIEW SNAPSHOT 101

FIGURE 41 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.: SWOT ANALYSIS 102